Wednesday, December 06, 2017 5:22:39 PM
NASH drug developers in the red after Madrigal's mid-stage success with MGL-3196
Dec. 6, 2017 12:37 PM ET|By: Douglas W. House, SA News Editor
Investors are swarming over Madrigal Pharmaceuticals (MDGL +79.8%) after it reported positive results from a Phase 2 clinical trial assessing MGL-3196 in NASH patients. Certain would-be NASH players have been brushed aside in early trading.
Selected tickers: (MNOV +0.9%)(GLMD)(RGLS -2.2%)(ICPT +0.4%)(CNAT -2.4%)(VBLT +1.6%)(GALT -8.7%)(SHPG -1.5%)(AGN +0.3%)(HZNP -1.2%)(OTCPK:GNFTF -5%)(VKTX +2.6%)
I'm not familiar with MDGL's entry...whether it's a targeted approach for a single issue (NASH), or a multi-faceted potential like CNAT. CNAT's game is for combination therapies focused on multiple liver issues not exclusively NASH.
From CNAT Website:
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM